4DMEDICAL LIMITED (4DX)

The suspension of trading in the securities of 4D Medical Limited will be lifted from the commencement of trading on Thursday, 4 March 2021, following the release by 4DX of an announcement regarding a capital raise.

4DMedical receives commitments for A$40.0 million via a Placement at A$1.55 per share. The Placement received significant support from new and existing institutional and sophisticated investors from both Australia and overseas. Proceeds from the Placement will primarily fund, in conjunction with the $28.9m of MRFF funding, the development and commercialisation of the world's first dedicated lung function scanner "“ XVD Scanner. It was a commitment of the grant bid to the MRFF that 4DMedical provide new capital for the development of the XVD Scanner. The Placement proceeds will also provide balance sheet flexibility to pursue identified growth opportunities. XVD Scanners will be integrated with 4DMedical's proprietary XV Technology, significantly increasing the addressable revenue opportunity and driving the adoption of the Company's core Software-as-a-Service (SaaS) offering which remains 4DMedical's primary focus. "¢ The Company anticipates that Generation One XVD Scanners will be placed in hospitals for clinical trials in early 2022. The Company will also offer a Share Purchase Plan (SPP) of up to A$3.0 million at A$1.55 to provide eligible shareholders the opportunity to participate in the capital raise "“ details will be released to shareholders shortly. Andreas Fouras, 4DMedical's CEO, will host a webinar to discuss the grant, capital raising and the Company's SaaS offering at 9:30am AEDT today, Thursday 4 March 2021.

Australian Lung Health Initiative Pty Ltd, a consortium incorporated and led by 4DMedical, has been awarded $28.9 million in funding over the next five years as part of the Federal Government's Medical Research Future Fund Frontier Health and Medical Research initiative. The funding will be used by ALHI to develop two generations of dedicated, low dose lung function scanners that provide safe, easy and rapid lung analysis of adults and children. 4DMedical has been granted the exclusive right to commercialise XVD Scanners and will be responsible for the global sale and marketing of XVD Scanners in the field of lung health. XVD Scanners will be integrated with 4DMedical's proprietary XV Technology, significantly increasing the addressable revenue opportunity and driving the adoption of the Company's Softwareas-a-Service (SaaS) offering at medical institutions. "¢ ALHI was previously awarded $1.1 million in Stage One funding that was used to successfully develop and deliver a Generation One XVD Scanner concept. Stage Two of the project aims to bring Generation One and Generation Two scanners to commercialisation, with first units expected to be deployed in Australian hospitals for clinical trials within the next 12 months.

The securities of 4D Medical Limited will be suspended from quotation immediately under Listing Rule a17.2, at the request of 4DX, pending the release of an announcement regarding a capital raise.

listed entity carried for record purposes only